# Sangamo Therapeutics

uses zinc-finger transcription factors rather than dCas9 as its DNA-binding scaffold, partnering with Genentech to develop an epigenetic Alzheimer's therapy and holding patent filings on zinc-finger repressors targeting alpha-synuclein.

Source: https://en.bioecon.ru/companies/sangamo-therapeutics/
Updated: 2026-07-03

- Country: United States

## Technologies

- [Epigenome editing](https://en.bioecon.ru/technology/epigenome-editing/)